Tutt A L, Stevenson F K, Slavin S, Stevenson G T
Immunology. 1985 May;55(1):59-63.
An analysis has been carried out to investigate the ability of neoplastic cells from the mouse B-cell leukaemia (BCL1) to secrete idiotypic IgM. Tumour cells taken from the spleen and placed in short-term culture without stimulation secreted quite large amounts of idiotypic IgM with a mean value for six animals +/- SD of 11,5000 +/- 6800 molecules of pentamer/cell/hr, with levels increasing steadily over a 7-hr period. Tumour cells from the blood of matched animals also secreted idiotypic IgM in amounts generally less than the spleen cells (4100 +/- 2000 molecules/cell/hr. The IgM produced was found to be mainly pentameric, with some material of lower molecular weight. This idiotypic IgM could also be detected in the serum of leukaemic animals as pentameric IgM, and amounts increased during tumour development to 1-2 mg/ml in the terminal phase of disease. Since binding of anti-idiotypic antibody to tumour cells is inhibited by this material, it should be taken into account in immunotherapeutic schedules involving such antibody. However, it also presents a useful marker of disease, and perhaps of response to therapy.
已开展一项分析，以研究源自小鼠B细胞白血病（BCL1）的肿瘤细胞分泌独特型IgM的能力。取自脾脏并在无刺激条件下进行短期培养的肿瘤细胞分泌了相当大量的独特型IgM，六只动物的平均值±标准差为115000±6800个五聚体分子/细胞/小时，且在7小时内水平稳步上升。来自匹配动物血液的肿瘤细胞也分泌独特型IgM，其数量通常少于脾细胞（4100±2000个分子/细胞/小时）。所产生的IgM主要为五聚体，还有一些分子量较低的物质。这种独特型IgM在白血病动物血清中也可检测到为五聚体IgM，且在肿瘤发展过程中数量增加，在疾病末期达到1 - 2毫克/毫升。由于抗独特型抗体与肿瘤细胞的结合受该物质抑制，在涉及此类抗体的免疫治疗方案中应予以考虑。然而，它也是疾病的一个有用标志物，或许还是对治疗反应的标志物。
